Related Experiment Video

Updated: Jun 23, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Preferential inhibition of the oncogenic form of RasH by mutations in the GAP binding/"effector" domain

C L Farnsworth1, M S Marshall, J B Gibbs

  • 1Department of Biochemistry, Tufts University Health Sciences Campus, Boston, Massachusetts 02111.

Cell
|February 8, 1991
PubMed

Insights

Mutations in RasH proteins selectively reduce oncogenic forms while sparing normal RasH function. This suggests a targeted therapeutic strategy against Ras-driven cancers by inhibiting the Ras protein's effector domain.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Ras proteins are key regulators of cellular signaling pathways.
  • Mutations in Ras genes are common drivers of human cancers, particularly oncogenic Ras.
  • Targeting oncogenic Ras while preserving normal Ras function is a significant therapeutic challenge.

Purpose of the Study:

  • To investigate the effects of specific RasH mutations (D33H/P34S and D38N) on the transforming activity of both normal and oncogenic RasH proteins.
  • To elucidate the impact of these mutations on Ras protein interactions with GTPase-activating protein (GAP) and downstream signaling.
  • To explore the potential of these mutations as a basis for developing targeted cancer therapies.

Main Methods:

  • Site-directed mutagenesis to introduce D33H/P34S and D38N mutations into RasH constructs.
  • Assays to measure the transforming activity of wild-type and mutant RasH proteins in cell culture.
  • Yeast adenylyl cyclase stimulation assays to assess downstream coupling efficiency.
  • Co-immunoprecipitation assays to evaluate GTPase-activating protein (GAP) binding affinity.

Main Results:

  • The D33H/P34S mutation significantly reduced the transforming activity of oncogenic RasH (G12V and Q61L) by 400- and 20-fold, respectively.
  • This mutation did not affect the transforming activity of normal RasH or its ability to restore Ras pathway function.
  • Mutations decreased downstream coupling but were partially offset by reduced GAP binding in normal RasH, leading to elevated GTP-bound Ras.
  • In oncogenic RasH, mutations decreased coupling, and reduced GAP binding did not compensate due to lack of GAP-stimulated GTPase activity.

Conclusions:

  • Specific RasH mutations can selectively impair oncogenic Ras transforming activity without compromising normal Ras function.
  • These mutations affect Ras downstream signaling and GAP interaction, offering insights into Ras regulation.
  • Targeting the GAP-binding/effector domain of Ras proteins presents a promising strategy for the preferential inactivation of oncogenic Ras in human tumors.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Rab Cascades01:25

Rab Cascades

Rab GTPases act in a regulated cascade during membrane fusion, helping the lipid bilayers mix. The Rab family of proteins are active when bound to GTP, and inactive when bound to GDP. Hence, they act as guanine nucleotide-dependent molecular switches. Rab-GTP recognizes and binds to long or short-range tethering proteins to capture the target vesicle. These tethers coordinate with SNAREs on the vesicle and the target membrane to assemble the trans SNARE complex that locks the mixing bilayers.
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...